• Gain Therapeutics will present findings from rexaceract’s Phase 1b Parkinson’s disease open-label extension on Nov. 13, 2026, in Milan.
• Rexaceract is being evaluated for Parkinson’s disease with or without a GBA1 mutation.
• Preclinical GT-04686 research will feature at the Nov. 11-14 IAPRD congress, followed by a Nov. 17 presentation at Neuroscience 2026.
• The Neuroscience presentation describes reduced neuropathology and improved motor and non-motor function in a preclinical GBA1 Parkinson’s disease model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870868) on November 05, 2026, and is solely responsible for the information contained therein.